Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SELLAS Life Sciences Group, Inc. Director's Dealing 2017

Jun 22, 2017

33651_dirs_2017-06-22_42494743-89c7-493e-92bd-a959d7b510d8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2017-06-20

Reporting Person: Nisi Rudolph (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-06-20 Common Stock S 500 $0.5461 Disposed 14864 Direct